Company: BGLC
Filing Date: 2025-04-30
Form Type: 8-K
Source: 0001477932-25-003114
Chunk: 1

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-30
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01

Regulation FD Disclosure.

On April 30, 2025, the Company issued a press release announcing that it had regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) and reaffirming its strategic focus on innovation, compliance, and long-term growth initiatives.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 (including Exhibit 99.1) is being furnished pursuant to Regulation FD and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities under that Section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.